CClinicalTrials.gg
Sign In
CompletedNCT00440141Updated Jan 2, 2008

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

A Phase 4 interventional study of latanoprost 0.005% eye drops and brimonidine 0.1% eye drops and latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-02.

Sponsored by Allergan · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

02

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Browse trials for

03

In context

Ocular Hypertension

649 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.

This study's enrollment of 40 is below the median of 120 across 510 interventional studies indexed under Ocular Hypertension.

Browse Ocular Hypertension studies →

Lead sponsor

Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Glaucoma or ocular hypertension in both eyes
  • Currently being treated with latanoprost 0.005% QD
  • IOP greater than or equal to 18mm Hg on latanoprost 0.005%
  • Best-corrected VA of 20/200 or better in each eye
  • Visual field within 6 months of study entry

Exclusion criteria

Exclusion Criteria:

  • Secondary glaucoma
  • Active intraocular inflammation or macular edema
  • Intraocular surgery or laser surgery within the past 3 months
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1

    Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops

  • Active comparator
    2

    Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

Interventions

  • Druglatanoprost 0.005% eye drops and brimonidine 0.1% eye drops

    latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

    Also known as: Xalatan®, Alphagan® P

  • Druglatanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

    latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

    Also known as: Xalatan®, Azopt®

06

What researchers measure

Primary outcomes

  1. IOP

    Time frame: Month 3

Secondary outcomes

  1. Tolerability

    Time frame: Month 3

07

Study locations

1 site
  • Atlanta, Georgia, United States
08

References and documents

Publications

  • Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008 May;24(5):1435-42. doi: 10.1185/030079908x301848. Epub 2008 Apr 9. PubMed 18402717 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00440141
Lead sponsor
Allergan
First posted
Feb 26, 2007
Start date
Jul 2006
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Jan 2, 2008

Study contacts

Medical Affairs
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ocular Hypertension→

Other studies from this sponsor

Allergan

Start the discussion